Home Applications Pharmaceutical & Biopharmaceutical ManufacturingVaccine Manufacturing

Vaccine Manufacturing: Process Development and Expertise

Vaccine Development and Manufacturing Capabilities

Vaccines are among the most cost-effective health interventions against pathogens and other infectious diseases, saving millions of lives annually while improving quality of life for countless others. Growing global demand, however, poses severe challenges for vaccine manufacturers. Each new pathogen or outbreak adds to the variety of vaccine types and manufacturing methods needed, preventing establishment of robust processing templates that could improve overall effectiveness, safety, and affordability.

From a manufacturing perspective, many factors are critical to accelerating vaccine production and meeting performance goals. These include predictable scale-up, optimal upstream productivity, robust impurity removal, maximized downstream recovery, speed to clinic, patient safety, and regulatory compliance. Achieving process improvements can drive success for all of the vaccine development platforms described below, but innovative technologies and a high level of application expertise are required.

Request Information

VACCINE MANUFACTURING PLATFORMS

Virus-Based Vaccines

Virus-Based Vaccines

Virus-like Particle (VLP) Vaccines

Virus-like Particle (VLP) Vaccines

Viral Vector Vaccines

Viral Vector Vaccines

Plasmid DNA Vaccines

Plasmid DNA Vaccines

mRNA Vaccines

Conjugated Polysaccharide Vaccines

Conjugated Polysaccharide Vaccines

Related Articles

Cell Harvest, Lysis, Neutralization and Clarification of Plasmid DNA (pDNA) for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications
An overview of the cell harvest, lysis, neutralization, and clarification steps used for pDNA purification along with case study and practical advice.
Choosing the Optimal Cell Culture Media for Vaccine Production
Choosing the Optimal Cell Culture Media for Vaccine Production
Cost Modeling Vaccine Manufacturing: Estimate Production Costs for mRNA and other Vaccine Modalities
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Egg-based and Cell-based Influenza Vaccine Manufacturing Methods
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
Manufacturing Strategies for mRNA Vaccines and Therapeutics
mRNA technology uses non-viral delivery systems and offers a great deal of versatility. Delivery of an mRNA into the cytosol of a cell can induce the production of a target protein which can function as a therapeutic or prophylactic, act as an antigen to trigger an immune response for vaccination purposes, replace a defective protein or activate an anti-tumor response.
See All (7)

Find More Articles

Related Resources

e-Book: Enabling Capabilities & Solutions for all Vaccine Platforms
Brochure: Vaccine Bioprocessing Handbook
Brochure: Enabling Vaccines Production - Solving Challenges Together
Biopharmaceutical Applications Guide
White Paper: Developing an Accelerated and More Cost-Effective Single-Use Adenoviral Vector Vaccine Manufacturing Process

White Paper: How Pandemics and Outbreaks Have Influenced the Adoption of Single-use Vaccine Manufacturing
Brochure: Flexible Manufacturing of Vaccine
White Paper: Vaccine Manufacturing - Collaboration Helps to Overcome Vaccine Process Challenges

Related Applications

Gene Therapy Manufacturing

Growing use of gene therapies is driving rapid innovation in an evolving global market. Manufacturers bringing new gene therapies to life face complex challenges, requiring an experienced partner capable of integrating vector manufacturing, testing, safety, process development, and regulatory compliance.

Cell Therapy Manufacturing

Introducing a new cell therapy demands optimal performance in upstream and downstream processing, process development, testing, and manufacturing. World-class products and partners are critical to success, speeding advancement of therapeutics that are effective, safe, and affordable.

Pharma & Biopharma Startup Hub

Your new molecule or therapy begins its journey here. Find solutions and resources to navigate your path to successful drug discovery, development, and commercialization.

Virus-like Particles (VLPs) Vaccine Manufacturing

VLP vaccine manufacturers must optimize upstream productivity with reliable scale-up, achieve yield and efficiency goals with robust impurity removal, maximize downstream recovery, and ensure patient safety. Merck’s integrated portfolio, regulatory and applications expertise can help address these process challenges.

Virus-Based Vaccine Manufacturing

Manufacturing viral vaccines is complex and there is no templated approach. Each process must be tailored to the shape, size, nature, physico-chemical behavior, stability, and host specificity of the virus. Learn all about this core platform technology and how expertise—empowered by collaboration— can overcome manufacturing challenges.

Viral Vector Vaccine Manufacturing

A relatively templated manufacturing process can be used to produce live vector vaccines. Challenges exist, however, and include yield loss due to sterile filtration, vector aggregation and scaling adherent cultures. Learn all about this core platform technology and how expertise—empowered by collaboration— can overcome manufacturing challenges.

Plasmid DNA Vaccines Manufacturing

Manufacturing plasmid DNA (pDNA) vaccines is challenging due to low productivity of fermentation and the large size and negative charge of the plasmid. The lysate can also be highly viscous with contaminants similar to pDNA leading to low resolution separation. Learn all about this core platform technology and how expertise—empowered by collaboration— can overcome manufacturing challenges.

mRNA Vaccine Process Manufacturing

Development and manufacturing of mRNA vaccines is relatively simple, scalable and extremely rapid. A range of technologies are available to increase process productivity, maximize yield, recovery and impurity removal. Learn all about this new platform technology and how expertise—empowered by collaboration—can refine mRNA approaches.

Related Product Categories

Bioprocessing Mobius^® Single-Use Bioreactors

The Mobius^® Bioreactor family includes the bench scale (2 mL and 3 L), pilot, clinical and commercial manufacturing (50 – 2,000 L) single-use bioreactors that enable cell culturing capabilities from early process development through commercial batch production.

Upstream Process Chemicals

Our portfolio of upstream process chemicals provides biopharmaceutical manufacturers with high-quality raw materials for every stage from research to commercial application, backed by supply chain transparency, reliable sourcing, and best-in-class regulatory support.

Virus Inactivation

Our virus inactivation offerings provide biopharma manufacturers with improved options for HTST pasteurization, low pH and chemical/detergent treatment, ensuring virus-free products while simplifying compliance and documentation.

Bioprocessing Liquid Cell Culture Media & Buffers

We offer the industry’s highest quality sterile liquid capabilities, supplying ready-to-use cell culture media, buffers, CIP and SIP products from GMP facilities worldwide to optimize your biopharma production.

Bioprocessing Cell Culture Media

Our off-the-shelf and customizable bioprocessing cell culture media (CCM) products enhance productivity in upstream mAb, vaccine, gene/cell therapy processes.

Clarification Filter Holders and Systems for Bioprocessing

Our flexible hardware and systems for disposable depth filters are ideal for clarification at pilot and process scales, featuring the modular Pod device that enables scale-up and scale-down within the same footprint.

Downstream Process & Formulation Chemicals

Our broad portfolio of downstream chemicals simplifies raw material specification with optimized quality attributes for all your applications – while providing industry-leading support and documentation to help navigate regulatory challenges, manage risks, and improve processes.

Single-Use Mixers

Our complete range of Mobius^® single-use mixing solutions can meet your needs for mixing pharmaceutical ingredients from intermediate to final drug products, as well as preparation of process solutions such as buffers and media.

Collaboration - Featured Announcements

Merck and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity
Merck Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?